MNG1211
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.557
- MYC_TARGETS_V2+0.551
- G2M_CHECKPOINT+0.541
- E2F_TARGETS+0.502
- UNFOLDED_PROTEIN_RESPONSE+0.468
- PROTEIN_SECRETION+0.427
- MTORC1_SIGNALING+0.399
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.389
- INTERFERON_ALPHA_RESPONSE+0.380
- MITOTIC_SPINDLE+0.371
Top 10 suppressed
- KRAS_SIGNALING_DN-0.319
- BILE_ACID_METABOLISM-0.285
- COAGULATION-0.178
- MYOGENESIS-0.172
- HYPOXIA-0.156
- ALLOGRAFT_REJECTION-0.140
- PANCREAS_BETA_CELLS-0.114
- PEROXISOME-0.104
- ESTROGEN_RESPONSE_LATE-0.098
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934964 | — | — | 0.898 |
| 2 | 592CC5DC-4DB7-4961-AB2B-89C8FE4A83D3 | — | — | 0.895 |
| 3 | E0DE33EA-C3DF-478E-9C4D-86E3C7B3A1D9 | — | — | 0.887 |
| 4 | E0173AAB-678A-46E0-B701-C79A6BE9B9D8 | — | — | 0.877 |
| 5 | C4A69C6F-E199-43CF-9DA1-94E1B3AE7388 | — | — | 0.868 |
| 6 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.865 |
| 7 | SRR934878 | — | — | 0.860 |
| 8 | C4C1F171-9B72-4527-9C03-39C2C00A5B6C | — | — | 0.857 |
| 9 | MDT-AP-3328 | Med | Medulloblastoma | 0.856 |
| 10 | SRR934915 | — | — | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.557 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.551 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.541 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.502 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.468 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.427 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.399 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.389 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.371 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.367 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.354 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.327 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.211 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.199 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.185 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.184 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.163 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.112 | Inavolisib | — uncovered |